Surgery after initial treatment for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether additional treatment before surgery can improve outcomes for patients with esophageal squamous cell carcinoma. It focuses on those who have already received initial therapy and are scheduled for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with squamous cell carcinoma of the esophagus (a type of cancer that starts in the flat cells lining the esophagus).
- You have received initial treatment (such as chemotherapy, radiation, or immunotherapy) before surgery.
- Your cancer is at a stage where it can be surgically removed (stage II–III, and not spread too far).
- You are generally healthy enough for surgery, with normal blood, lung, liver, and kidney function.
- You have not had immunotherapy in the past and do not have autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of chemotherapy, radiation therapy, and an immunotherapy drug before surgery for a type of esophageal cancer (squamous cell). The goal is to see if this approach helps shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This Phase 3 trial looks at the best next step after surgery for thoracic esophageal squamous cell cancer that has spread to nearby lymph nodes. It compares adding chemotherapy, adding chemoradiation (chemotherapy plus radiation), or not adding additional treatment right away, to see which approach works best and is safest.
This trial tests the best way to treat locally advanced squamous cell esophageal cancer: either chemoradiation followed by planned surgery, or monitoring with surgery only if needed. It may help you choose a strategy that controls the cancer while aiming to reduce unnecessary procedures.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.